Actinogen Medical company info

What does Actinogen Medical do?
Actinogen (ASX:ACW) is a clinical-stage biopharmaceutical company developing innovative treatments for cancer and other diseases. The company's lead product candidate, Xanamem, is a novel small molecule that targets the DNA damage response pathway. Xanamem is currently in Phase 2 clinical trials for the treatment of advanced pancreatic cancer and in Phase 1 clinical trials for the treatment of advanced solid tumours and acute myeloid leukaemia. Actinogen is also developing a second product candidate, ACT-701, which is a targeted therapy that is currently in preclinical development for the treatment of solid tumours.
Actinogen Medical company media
Company Snapshot

Is Actinogen Medical a public or private company?

key
Ownership
Public

How many people does Actinogen Medical employ?

people
Employees
17

What sector is Actinogen Medical in?

pie chart
Sector
Health Care

Where is the head office for Actinogen Medical?

location pin
Head Office
New South Wales, Australia

What year was Actinogen Medical founded?

founded flag
Year Founded
1999
What does Actinogen Medical specialise in?
/Biopharmaceutical /Alzheimer /Therapy /Health /Biotech

What are the products and/or services of Actinogen Medical?

Overview of Actinogen Medical offerings
Xanamem: A novel small molecule that targets the DNA damage response pathway, currently in Phase 2 clinical trials for the treatment of advanced pancreatic cancer and in Phase 1 clinical trials for the treatment of advanced solid tumours and acute myeloid leukaemia.
ACT-701: A targeted therapy that is currently in preclinical development for the treatment of solid tumours.
Cognitive impairment in early Alzheimer's Disease: A Phase 2b trial is ongoing to evaluate the efficacy and safety of Xanamem in patients with the early stages of Alzheimer's Disease.
Cognitive impairment in Major Depressive Disorder: A Phase 2a trial is currently enrolling patients to evaluate the efficacy and safety of Xanamem in patients with Cognitive Impairment and Depressive Disorder.
Anxiety, sleep & behavioural problems in Fragile X Syndrome: A Phase 2a trial is planned to evaluate the efficacy and safety of Xanamem in patients with Fragile X Syndrome.
Cortisol Hypothesis: Actinogen is developing therapies that target the cortisol hypothesis, which states that dysregulated brain cortisol plays a role in the development and progression of a variety of neurological diseases.

Who is in the executive team of Actinogen Medical?

Actinogen Medical leadership team
  • Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.
    Dr. Steven G. Gourlay ), FRACP, M.B.A., MBBS (M.D., Ph.D.
    MD, CEO & Director
  • Dr. Dana C. Hilt M.D.
    Dr. Dana C. Hilt M.D.
    Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board
  • Prof. Paul  Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.
    Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.
    Head of Clinical Pharmacology & Lead Physician and Depression
  • Mr. William Edward Souter BCom, IPAA, LLB (Adel)
    Mr. William Edward Souter BCom, IPAA, LLB (Adel)
    Chief Financial Officer
  • Mr. Michael  Roberts
    Mr. Michael Roberts
    Head of Investor Relations & Corporate Communications
  • Dr. Fujun  Li Ph.D.
    Dr. Fujun Li Ph.D.
    Head of Manufacturing
  • Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.
    Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.
    Company Secretary